1Hwang YY, Liang R. Antifungal prophylaxis and treatment in patients with hematological malignancies[J]. Expert Rev Anti Infect Ther, 2010,8(4) :397-404. 被引量：1
2Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazo|e prophylaxis in patients with neutropenia[J]. N Engl J Med, 2007,356(4):348 -359. 被引量：1
3Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft versus-host disease [J]. N EnglJ Med, 2007,356(4) :335-347. 被引量：1
4Vehreschild J J, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with a- cute myelogenous leukaemia (AMID : a 6 year experience of the Cologne AML cohort [J]. J Antimicrob Chemother, 2010,65(7) : 1466-1471. 被引量：1
5Sanchez-Ortega I, Patino B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posacon- azole vs itraconazole in allogeneic blood and marrow trans- piantation[J]. Bone Marrow Transplant, 2011,46(5) : 733- 739. 被引量：1
6Winston DJ, Bartoni K, Territo MC, et al. Efficacy, safety, and breakthrough infections associated with standard long- term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients[J]. Biol Blood Marrow Trans- plant, 2011,17(4) :507-515. 被引量：1
7Zoller E, Valente C, Baker K, et al. Development, clinical u- tility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections[J]. Drug Des DeveI T her, 2010,4:299- 311. 被引量：1
8Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet[J], Br J Haematol, 2011,153(6):681-697. 被引量：1
9Walsh TJ, Raad I, Patterson TF, et aI. Treatment of inva- sire aspergillosis with posaconazole in patients who are refrae tory to or intolerant of conventional therapy: an externally controlled trial[J]. Clin Infect Dis, 2007,44(1):2- 12. 被引量：1
10Raad II, Hanna HA, Boktour M, et al. Novel antifungal a-gents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphoteriein B alone or in combination with caspofungin [J]. Leukemia, 2008,22 (3) 496-503. 被引量：1
